1.55  -0.17 (-9.88%)		09-16 16:00
Open: 1.67 High: 1.7 Volume: 1,035,372		Pre. Close: 1.72 Low: 1.55 Market Cap: 70(M)

Short term
Mid term
Targets	6-month :	2.36	1-year :	3.02
Resists	First :	2.02	Second :	2.58
Pivot price	1.9
Supports	First :	1.1	Second :	0.91
MAs	MA(5) :	1.69	MA(20) :	1.76
	MA(100) :	1.09	MA(250) :	1.03
MACD	MACD :	0.1	Signal :	0.2
%K %D	K(14,3) :	27	D(3) :	33.1
RSI	RSI(14): 46.7
52-week	High :	2.58	Low :	0.7

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ RNXT ] has closed above bottom band by 22.6%. Bollinger Bands are 249.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 28 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	1.7 - 1.71	1.71 - 1.72
Low:	1.52 - 1.54	1.54 - 1.55
Close:	1.53 - 1.55	1.55 - 1.57

RenovoRx, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for solid tumor malignancies. The company's primary investigational therapy, RenovoGem, is an innovative drug and device combination. It integrates intra-arterial gemcitabine with the RenovoCath system, currently progressing through pivotal Phase III clinical trials for the treatment of locally advanced pancreatic cancer. Established in 2009, RenovoRx, Inc. maintains its headquarters in Los Altos, California.

Wed, 16 Sep 2026
RNXT Q2 2026 Earnings: Narrower-Than-Expected Loss Beats Consensus, Yet Shares Slip - Earnings Revision Downgrade - dars.gov.et

Tue, 15 Sep 2026
CFO of RenovoRx (RNXT) awarded 80,000 RSUs - Stock Titan

Tue, 25 Aug 2026
RenovoRx study: About 51% of a chemotherapy drug was extracted at the tumor site - Stock Titan

Fri, 21 Aug 2026
RenovoRx regains Nasdaq minimum bid price compliance - Investing.com

Wed, 12 Aug 2026
RenovoRx, Inc. (RNXT) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance

Tue, 11 Aug 2026
RenovoRx Inc (RNXT) Q2 2026: Everything You Need To Know Ahead Of Earnings - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	45 (M)
Shares Float	39 (M)
Held by Insiders	3.4 (%)
Held by Institutions	20.3 (%)
Shares Short	674 (K)
Shares Short P.Month	328 (K)

EPS	-0.32
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.2
Profit Margin	0 %
Operating Margin	-368.5 %
Return on Assets (ttm)	-65 %
Return on Equity (ttm)	-125.3 %
Qtrly Rev. Growth	115.4 %
Gross Profit (p.s.)	0.03
Sales Per Share	0.04
EBITDA (p.s.)	-0.29
Qtrly Earnings Growth	0 %
Operating Cash Flow	-12 (M)
Levered Free Cash Flow	-7 (M)

PE Ratio	-5
PEG Ratio	0
Price to Book value	7.74
Price to Sales	35.32
Price to Cash Flow	-5.9

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.